Published in Healthcare Finance, Tax and Law Weekly, June 14th, 2006
"We are pleased to be included in the NASDAQ Biotechnology Index and believe that our selection to this index is further recognition of our consistent progress and achievements," said Uli Hacksell, PhD, CEO of Acadia. "We look forward to continuing to execute on our strategy of building a broad pipeline of innovative therapies to treat central nervous system disorders and other areas of unmet medical need."
Launched in 1993, the NASDAQ Biotechnology Index includes companies that are listed on the NASDAQ national market and meet minimum...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Healthcare Finance, Tax and Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.